NoIR 87% Yellow Fitover Sunglasses Large L50
by NoIR
Last verified June 19, 2026 · classified April 26, 2026
What it is
Summary
AI-generated from vendor-published content · April 26, 2026
These yellow-tinted fitover glasses block all UV and blue light while transmitting 87% of visible light, which enhances contrast and makes details easier to distinguish in low-contrast situations. They're designed for people with conditions like macular degeneration or other low vision issues who need glare control without losing brightness — the yellow tint is specifically chosen to maximize perceived contrast rather than darken the environment. The glasses fit over standard prescription eyewear and include side shields to block peripheral glare, making them a complete, ready-to-wear solution right out of the box. The high light transmission (87%) means they provide minimal darkening outdoors on very bright days, so they're best suited for indoor use or overcast conditions rather than full sun.
Quick Facts Catalog facts · auto-generated
- AT Act lending
- Out of pocket
What Setup Looks Like
- Out of the box
- Unfold the glasses and place over existing prescription eyewear or wear alone.
- Side shields are built in — no adjustment needed.
Getting it
Try Before You Buy
Devices like this are often available to borrow through your state's AT Act program — typically free or low-cost — so you can try it before buying or pursuing funding.
Where to Get It
Some links may be affiliate links — WhatCanHelp may earn a small commission from purchases at no extra cost to you. More on affiliates →
As an Amazon Associate we earn from qualifying purchases.
Wondering how equipment like this gets paid for? See the official funding programs in your state.
Compare & explore
Sources & fine print
Vendor facts (name, price, platforms, vendor link) sourced from NoIR — view on vendor site; last verified June 19, 2026.
Classification & description AI-generated from vendor-published content on April 26, 2026 · confidence: high. Vendor specs may lag; verify before relying on details in a clinical or funding artifact.